FDA Approves New Treatments For Triple-Negative Breast Cancer And Chronic Hepatitis D

FDA Approves New Treatments For Triple-Negative Breast Cancer And Chronic Hepatitis D Datopotamab deruxtecan gained approval as a first-line option for triple-negative breast cancer patients ineligible for immunotherapy, MedPage Today reports, while the bulevirtide injection became the first FDA-approved treatment for chronic hepatitis delta virus. Also: Researchers have identified a protein that facilitates the spread of Parkinson’s disease in the brain. https://kffhealthnews.org/morning-breakout/pharma-and-tech-3/